Clinical Trial

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Name: A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis — clinical trial record (NCT07399067)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-02.

Status change: Not Yet Recruiting → Recruiting 2026-02-11

Trial Details

NCT Number	NCT07399067
Lead Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Atopic Dermatitis
Enrollment	120 participants
Start Date	2026-02-06
Primary Completion	2027-03-23 (estimated)
Study Completion	2027-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-02-13